全文获取类型
收费全文 | 2483篇 |
免费 | 209篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 80篇 |
妇产科学 | 75篇 |
基础医学 | 347篇 |
口腔科学 | 56篇 |
临床医学 | 204篇 |
内科学 | 643篇 |
皮肤病学 | 35篇 |
神经病学 | 202篇 |
特种医学 | 63篇 |
外科学 | 312篇 |
综合类 | 34篇 |
一般理论 | 1篇 |
预防医学 | 246篇 |
眼科学 | 31篇 |
药学 | 157篇 |
中国医学 | 8篇 |
肿瘤学 | 159篇 |
出版年
2023年 | 12篇 |
2022年 | 24篇 |
2021年 | 55篇 |
2020年 | 43篇 |
2019年 | 56篇 |
2018年 | 77篇 |
2017年 | 45篇 |
2016年 | 57篇 |
2015年 | 59篇 |
2014年 | 73篇 |
2013年 | 82篇 |
2012年 | 115篇 |
2011年 | 144篇 |
2010年 | 91篇 |
2009年 | 73篇 |
2008年 | 128篇 |
2007年 | 118篇 |
2006年 | 118篇 |
2005年 | 125篇 |
2004年 | 121篇 |
2003年 | 117篇 |
2002年 | 88篇 |
2001年 | 86篇 |
2000年 | 101篇 |
1999年 | 89篇 |
1998年 | 30篇 |
1997年 | 22篇 |
1996年 | 15篇 |
1995年 | 19篇 |
1994年 | 16篇 |
1993年 | 21篇 |
1992年 | 57篇 |
1991年 | 44篇 |
1990年 | 42篇 |
1989年 | 40篇 |
1988年 | 31篇 |
1987年 | 40篇 |
1986年 | 45篇 |
1985年 | 24篇 |
1984年 | 15篇 |
1983年 | 19篇 |
1980年 | 6篇 |
1979年 | 9篇 |
1978年 | 12篇 |
1977年 | 10篇 |
1976年 | 7篇 |
1974年 | 8篇 |
1969年 | 6篇 |
1967年 | 6篇 |
1966年 | 6篇 |
排序方式: 共有2694条查询结果,搜索用时 15 毫秒
131.
132.
133.
Background
Roux-en-Y gastric bypass (RYGB) reduces most of the obesity-related comorbidities known to increase the cardiovascular risk in obese subjects. The Framingham risk score (FRS) is designed to be independent of body weight and estimates the 10-year risk for coronary heart disease (CHD), myocardial infarction, stroke, cardiovascular disease (CVD), death from CHD, and death from CVD. Our aim was to evaluate the effectiveness of RYGB on improving the FRS when compared to a matched control group who underwent diabetes support and education program (DSE).Methods
In a prospective cohort study, we evaluated preoperatively and at 12 months, 61 morbidly obese subjects with diabetes. Thirty underwent laparoscopic RYGB, and 31 received 1 year of DSE, consisting of educational sessions on diet, nutrition, and exercise. Groups were matched for gender, age, weight, blood pressure, and cholesterol and triglyceride levels. Strict gender-specific FRS was used to assess the cardiovascular risk.Results
Excess weight-loss percentages (%EWL) were 55.6 ± 15.1 in the RYGB group and 1.2 ± 10.8 in the DSE group (P < 0.001). The two groups were matched for baseline FRS. RYGB patients experienced a significant decrease in all FRS, whereas control subjects did not show a significant decrease for the 10-year risk for CHD, CVD and death from CVD. The between-group differences for changes from baseline to 12 months in all FRS were significant. The 10-year risk reductions for CHD, MI, stroke, CVD, death from CHD, and death from CVD in the RYGB group relative to the DSE group were, respectively, 42, 48, 30, 39, 50, and 50 %. No correlations between reduction in FRS and %EWL were found after RYGB.Conclusions
A significant improvement in the 10 year estimated cardiovascular risk is observed in patients undergoing RYGB, but not in those who were offered usual medical therapy plus DSE. However, the effects of RYGB on FRS are independent of weight loss. 相似文献134.
Maite Augusta Gil-Ruiz Gil-Esparza Andrés José Alcaraz Romero Alfonso Romero Otero Nuria Gil Villanueva Eva Sanavia Morán Ana Rodríguez Sánchez de la Blanca Jorge Lorente Romero José María Bellón Cano 《Pediatric nephrology (Berlin, Germany)》2014,29(7):1265-1272
Background
Acute renal injury increases risk of death after cardiac surgery. The objective of the study was to evaluate the ability of the pediatric Risk, Injury, Failure, Loss, End-Stage Renal Disease (pRIFLE) criteria to characterize the development of postoperative renal damage in children after cardiopulmonary bypass (CPB) and to evaluate the relationship between the severity of kidney injury and mortality, pediatric intensive care unit (PICU) length of stay, and the duration of mechanical ventilation (MV).Methods
In this retrospective study including children undergoing CPB surgery during a 3-year period in the PICU of a tertiary hospital, demographic, clinical, surgery-related, and postoperative clinical data were collected. Kidney damage was assessed with pRIFLE criteria.Results
Four hundred and nine patients were included. Early acute kidney injury (AKI) was found in 82 patients (achieving categories Risk 44; Injury 16; Failure 22). Early AKI was associated with younger age (P?=?0.010), longer CPB, deep hypothermic circulatory arrest (DHCA) use, ICU stay >12 days, MV >4 days, and death (P?<?0.001). Controlling the effect of age, CPB, DHCA use, previous cardiac surgeries, and Risk Adjustment in Congenital Heart Surgery Surgical Severity Score (RACHS-1), early AKI development proved to predict ICU stay >12 days [odds ratio (OR) 3.5; 95 % confidence interval (CI) 1.9–6.5, P?<?0.001)] and need of MV >4 days (OR 5.1; 95 % CI 2.6–10.2, P?<?0.001).Conclusions
Early AKI when evaluated with the pRIFLE criteria can predict prolonged ICU stay, need of prolonged MV, and mortality. 相似文献135.
Stephanie Popping Valeria Cento Carole Seguin-Devaux Charles A. B. Boucher Adolfo de Salazar Eva Heger Orna Mor Murat Sayan Dominique Salmon-Ceron Nina Weis Henrik B. Krarup Robert J. de Knegt Oana Sndulescu Vladimir Chulanov David A. M. C. van de Vijver Federico García Francesca Ceccherini-Silberstein 《Viruses》2022,14(1)
Background: Approximately 71 million people are still in need of direct-acting antiviral agents (DAAs). To achieve the World Health Organization Hepatitis C elimination goals, insight into the prevalence and influence of resistance associated substitutions (RAS) is of importance. Collaboration is key since DAA failure is rare and real-life data are scattered. We have established a European collaboration, HepCare, to perform in-depth analysis regarding RAS prevalence, patterns, and multiclass occurrence. Methods: Data were extracted from the HepCare cohort of patients who previously failed DAA therapy. Geno—and subtypes were provided by submitters and mostly based on in-house assays. They were reassessed using the Comet HCV subtyping tool. We considered RAS to be relevant if they were associated with DAA failure in vivo previously reported in literature. Results: We analyzed 938 patients who failed DAA therapy from ten different European countries. There were 239 genotypes (GT) 1a, 380 GT1b, 19 GT2c, 205 GT3a, 14 GT4a, and 68 GT4d infections. Several unusual subtypes (n = 15) (GT1b/g/l, GT3b, GT4k/n/r/t) were present. RAS appeared in over 80% of failures and over a quarter had three or more RAS. Multiclass RAS varied over target region and genotype between 0–48%. RAS patterns such as the Q30R + L31M and Q30R + Y93H in GT1a, the L31V + Y93H and L31V + Y93H for GT1b, and A30K + L31M and A30K/V + Y93H for GT3a all occurred with a prevalence below 5%. Conclusion: RAS occur frequently after DAA failures and follow a specific genotype and drug related pattern. Interpretation of the influence of RAS on retreatment is challenging due to various patterns, patients’ characteristics, and previous treatment history. Moving towards HCV elimination, an ongoing resistance surveillance is essential to track the presence of RAS, RAS patterns and gather data for a re-treatment algorithm. 相似文献
136.
137.
Type‐specific clinical characteristics of adenovirus‐associated influenza‐like illness at five US military medical centers, 2009–2014
下载免费PDF全文
![点击此处可从《Influenza and other respiratory viruses》网站下载免费的PDF全文](/ch/ext_images/free.gif)
138.
Heat-shock proteins as activators of the innate immune system 总被引:24,自引:0,他引:24
Wallin RP Lundqvist A Moré SH von Bonin A Kiessling R Ljunggren HG 《Trends in immunology》2002,23(3):130-135
Peptides bound or linked to heat-shock proteins (HSPs) of microbial or mammalian origin have been shown to elicit potent antigen-specific immunity. Some members of the HSP family, such as hsp60, hsp70, hsp90 and gp96, are able also to stimulate cells of the innate immune system directly and thus, act as 'danger'-signaling molecules. This effect is independent of HSP-associated peptides and, in many respects, resembles the effect of lipopolysaccharide (LPS). Here, we discuss the similarities between the responses to HSPs and LPS and also, emphasize that care must be taken when working with preparations of HSPs in experimental settings and interpreting experimental data. 相似文献
139.
Yael Gozlan Daniella Aaron Yana Davidov Maria Likhter Gil Ben Yakov Oranit Cohen-Ezra Orit Picard Oran Erster Ella Mendelson Ziv Ben-Ari Fadi Abu Baker Orna Mor 《Viruses》2022,14(3)
A comprehensive characterization of chronic HBV (CHB) patients is required to guide therapeutic decisions. The cumulative impact of classical and novel biomarkers on the clinical categorization of these patients has not been rigorously assessed. We determined plasma HBV-RNA and HBsAg levels, HBV in peripheral lymphocytes (PBMCs) and HBV mutation profiles in CHB patients. Patient demographics (n = 139) and classical HBV biomarkers were determined during a clinical routine. HBV-RNA in plasma and HBV-DNA in PBMCs were determined by RT-PCR. HBsAg levels were determined using Architect. In samples with HBV-DNA viral load >1000 IU/mL, genotype mutations in precore (PC), basal core promoter (BCP), HBsAg and Pol regions were determined by sequencing. Most patients (n = 126) were HBeAg-negative (HBeAgNeg) with significantly lower levels of HBV-RNA, HBV-DNA and HBsAg compared to HBeAg-positive (HBeAgPos) patients (p < 0.05). HBV genotype D prevailed (61/68), and >95% had BCP/PC mutations. Escape mutations were identified in 22.6% (13/63). HBeAgNeg patients with low levels of HBsAg (log IU ≤ 3) were older and were characterized by undetectable plasma HBV-DNA and undetectable HBV-RNA but not undetectable HBV-DNA in PBMCs compared to those with high HBsAg levels. In >50% of the studied HBeAgNeg patients (66/126), the quantitation of HBsAg and HBV-RNA may impact clinical decisions. In conclusion, the combined assessment of classical and novel serum biomarkers, especially in HBeAgNeg patients, which is the largest group of CHB patients in many regions, may assist in clinical decisions. Prospective studies are required to determine the real-time additive clinical advantage of these biomarkers. 相似文献
140.